STRATEC Biomedical AG / Key word(s): Final Results
STRATEC publishes 2012 Annual Report
- Sales at EUR 122.4 million (+5.0%; previous year: EUR 116.6m)
- EBIT at EUR 17.6 million (-19.3%; previous year: EUR 21.8m)
- More than 2,600 analyzer systems shipped (+12.2%)
- Earnings per share at EUR 1.19 (-9.8%; previous year: EUR 1.32)
- Equity ratio at 75.5%
- Reporting based on cost of sales method for first time
- Proposed dividend of EUR 0.50 per share (previous year: EUR 0.55)
- Update in company forecast for 2013 and 2014 planned for H1/2013
Birkenfeld, April 18, 2013
STRATEC Biomedical AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, TecDAX) today announced its final results for the financial year ending on December 31, 2012 with the publication of its 2012 Annual Report. These figures, prepared in line with International Financial Reporting Standards (IFRS), have been audited and granted an unqualified audit opinion.
Business and financial performance
The volume of sales from development services, whose recognition depends on the respective project stage, was relatively weak compared with the previous year. This stands in sharp contrast to the number and size of development projects that have been initiated and which will contribute to the company's further growth from 2015 onwards.
Sales and the EBIT margin were within the ranges communicated in the most recent company forecast for 2012 (sales: EUR 120 million to EUR 125 million; EBIT: 14% to 16%).
At EUR 14.0 million, consolidated net income fell 8.6% short of the previous year's figure of EUR 15.3 million. Earnings per share amounted to EUR 1.19 (previous year: EUR 1.32).
Outlook and guidance
Development in staff totals
The IFRS annual financial statements for 2012 have been prepared for the first time using the cost of sales method. Conversion from the total cost method previously used is intended to enhance international comparability of the financial statements with peer group companies. Here, items have in some cases been reclassified from development to sales-related expenses, a modification chiefly due to activities in the context of new project development work.
Furthermore, 2013 will also see a conversion in the method used to value projects. This conversion results from the adoption of a non-mandatory recommendation made by the German Financial Reporting Enforcement Panel (DPR) the implementation of which will be completed during the course of 2013. Further details can be found in the current Annual Report.
2012 Annual Report
The Annual General Meeting of STRATEC Biomedical AG will be held in Pforzheim on Thursday, June 6, 2013. The invitation to the Annual General Meeting will be forwarded to STRATEC shareholders via their depositing banks in good time ahead of the Annual General Meeting.
Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.
Further information can be obtained from:
End of Corporate News
18.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
|Company:||STRATEC Biomedical AG|
|Phone:||+49 (0)7082 7916 0|
|Fax:||+49 (0)7082 7916 999|
|Listed:||Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart|
|End of News||DGAP News-Service|